Evaluation of changes in the Hormone receptor, Her2 status and Ki-67 proliferation following administration of neoadjuvant chemotherapy in breast cancer

被引：0
|
作者：
Jelicic, I. [1 ]
Kapicl, T. Ivkovic [1 ]
Lakic, T. [1 ]
Miladinovic, M. [1 ]
Lovrenski, A. [1 ]
Hardi, L. Vuckovic [1 ]
机构：
[1] Gen Hosp Vrbas, Ctr Pathol, Novi Sad, Serbia
来源：
VIRCHOWS ARCHIV | 2015年 / 467卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-01-045
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study
    Chen, Yuhai
    Liu, Xiaoyan
    Yu, Keda
    Sun, Xiangyu
    Xu, Shouping
    Qiu, Pengfei
    Lv, Zhidong
    Zhang, Xinwen
    Guo, Ayao
    Xu, Yingying
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
  • [2] Changes in Hormone Receptor and Her2 Status After Neoadjuvant Chemotherapy in Breast Cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Yamac, Deniz
    Coskun, Ugur
    Yildiz, Ramazan
    Yaman, Emel
    Ozturk, Banu
    Benekli, Mustafa
    TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2010, 30 (02): : 469 - 473
  • [3] Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer
    Avci, Nilufer
    Deligonul, Adem
    Tolunay, Sahsine
    Cubukcu, Erdem
    Olmez, Omer Fatih
    Ulas, Arife
    Hartavi, Mustafa
    Kurt, Ender
    Evrensel, Turkkan
    JOURNAL OF BUON, 2015, 20 (01): : 45 - 49
  • [4] Stability of Estrogen Receptor (ER), Progesterone Receptor (PR), Ki-67 and HER2 Status in Breast Carcinomas After Neoadjuvant Chemotherapy (NAC)
    Ginter, Paula
    Nagar, Himanshu
    Liu, Yifang
    Shin, Sandra
    Varma, Sonal
    MODERN PATHOLOGY, 2015, 28 : 46A - 46A
  • [5] Stability of Estrogen Receptor (ER), Progesterone Receptor (PR), Ki-67 and HER2 Status in Breast Carcinomas After Neoadjuvant Chemotherapy (NAC)
    Ginter, Paula
    Nagar, Himanshu
    Liu, Yifang
    Shin, Sandra
    Varma, Sonal
    LABORATORY INVESTIGATION, 2015, 95 : 46A - 46A
  • [6] Discordance in hormone receptor and HER2 status in breast cancer during neoadjuvant chemotherapy
    Maeda, S.
    Tohyama, H.
    Tokai, H.
    Kamohara, Y.
    Nagata, Y.
    Fujioka, H.
    Itoh, M.
    BREAST, 2011, 20 : S73 - S73
  • [7] Breast cancer subtypes based on estrogen receptor, progesteron receptor, Her2 expression and Ki-67 proliferation: Clinicopathological evaluation
    Jelicic, I.
    Kapicl, T. Ivkovic
    Druzek, G.
    Lendjel, V.
    Lakic, T.
    Desancic, J.
    VIRCHOWS ARCHIV, 2015, 467 : S58 - S58
  • [8] Change in ER, PR, HER2 status and Ki-67 after primary chemotherapy in breast cancer
    Petit, A.
    Loayza, C.
    Perez Casanova, L.
    Canellas, J.
    Falo, C.
    Perez, J.
    Soler, T.
    Climent, F.
    Gil, M.
    Pernas, S.
    Condom, E.
    VIRCHOWS ARCHIV, 2014, 465 : S124 - S125
  • [9] The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer
    Pedrini, Jose Luiz
    Savaris, Ricardo Francalacci
    Schorr, Mario Casales
    Cambruzi, Eduardo
    Grudzinski, Melina
    Zettler, Claudio Galleano
    TUMORI JOURNAL, 2011, 97 (06): : 704 - 710
  • [10] Her2 negative luminal breast carcinoma and Ki-67 evaluation
    Pavlakis, Kitty
    Vrekoussis, Thomas
    Tsipoura, Anna
    Tsenga, Artemis
    Arapantoni-Dadioti, Petroula
    Gavresea, Theofani
    Messini, Irini
    Barbounis, Vassilis
    BREAST, 2012, 21 (04): : 529 - 533
12345